Replies to post #250171 on Biotech Values

[DewDiligence]

BMY acquires RYZB for $62.50/sh cash—a 104% premium to Friday’s close:

https://www.globenewswire.com/news-release/2023/12/26/2801050/0/en/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio.html

The nominal deal value is $3.6B.

RYZB IPOd only three months ago at $18.00 (#msg-172827912). Hence, the investment return during this 3-month period was 247% (~3,600% annualized)!

[DewDiligence]

AZN acquires GRCL for $10.00/ADS cash+CVR—a 62% premium to Friday’s close (excluding the CVR):

https://www.businesswire.com/news/home/20231225813821/en

The nominal deal value (excluding the CVR) is $1.0B.

AZN is evidently not concerned about the FDA investigation into CAR-T risk of secondary lymphoma (#msg-173310477, #msg-173335665).